Interest of Magnetic Resonance Imaging in the Diagnosis of Upper Urinary Tract Invasive Tumours

NCT07252882 | Not Yet Recruiting

• 1 other identifier: RC31/23/0389
• Study Type: interventional
• Target: 178
• Locations: 1 country
• Sites: 11

Brief Summary

Upper urinary tract invasive cancer magnetic resonance imaging diagnosis

Conditions

Magnetic Resonance Imaging (MRI); Urologic Cancer

Keywords

Upper urinary tract magnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

• Diagnostic validity (composite criteria sensitivity and specifcity) of a predefined magnetic resonance imaging sequence in the diagnosis of upper urinary tract invasive tumour

  Diagnostic validity (sensitivity and specifcity) of a predefined magnetic resonance imaging sequence in the diagnosis of upper urinary tract invasive tumour (taking as reference the pathological analysis \[gold standard\] or biopsy with 3 months Uro-CT).

  3 months

Study Arms (1)

Patients with upper urinary tract tumour

EXPERIMENTAL

Patients with upper urinary tract tumour and will have upper urinary tract magnetic resonance imaging

Radiation: Upper urinary tract magnetic resonance imaging

Interventions

Upper urinary tract magnetic resonance imaging RADIATION

Patients with a suspected malignant tumour of the upper urinary excretory tract based on the presence of a suspicious lesion on a uro-computed tomography scan will have a diagnostic magnetic resonance imaging of the urinary tract with Gadolinium-based contrast agents

Patients with upper urinary tract tumour

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient over 18 years of age with a suspected upper urinary tract tumour based on the presence of a suspicious lesion on a uro-computed tomography scan
• Have given free, informed and signed consent
• Be affiliated to a social security scheme

You may not qualify if:

• Renal failure not allowing the injection of iodinated contrast media (Glomerular filtration rate \<30mL/min)
• Subject under legal protection (guardianship or curatorship)
• Pregnant or breastfeeding woman
• Contraindication to magnetic resonance imaging (patient with non-magnetic resonance imaging compatible equipment, claustrophobia preventing magnetic resonance imaging)
• Acide gadoteric hypersensibility

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (11)

Hôpital Pellegrin

Bordeaux, France, 33000, France

Location

Hôpital Claude Huriez

Lille, France, 59037, France

Location

Institut Paoli Calmettes

Marseille, France, 13009, France

Location

Clinique Beau Soleil

Montpellier, France, 34070, France

Location

Hôpital Lapeyronie

Montpellier, France, 34295, France

Location

Hôpital Saint-Louis

Paris, France, 75010, France

Location

Hôpital de la Pitié Salpêtrière

Paris, France, 75013, France

Location

Hôpital Européen Georges Pompidou

Paris, France, 75015, France

Location

Clinique La Croix du Sud

Quint-Fonsegrives, France, 31130, France

Location

CHU de Toulouse

Toulouse, France, 31059, France

Location

Clinique Pasteur

Toulouse, France, 31076, France

Location

MeSH Terms

Conditions

Urologic Neoplasms

Condition Hierarchy (Ancestors)

Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urologic Diseases

Central Study Contacts

Thomas PRUDHOMME, MD

CONTACT

0561322748; prudhomme.t@chu-toulouse.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 20, 2025
• First Posted: November 28, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: November 28, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (11)